Browse by category

Fractyl’s Rejuva platform demonstrates potent and durable effects of a single dose of a human GLP-1 pancreatic gene therapy transgene vs semaglutide for diabetes and obesity

Fractyl Health has revealed promising new preclinical findings for the first clinical candidate in its Rejuva pancreatic gene therapy...

GLP-1-based pancreatic gene therapy maintained weight loss after semaglutide withdrawal in rodents

Fractyl Health has revealed that preclinical findings from its Rejuva gene therapy platform, presented at the World Congress Insulin...

Fractyl expands ERASE Task Force to study underlying GLP-1-based pancreatic gene therapy for T2DM

Fractyl Health has expanded an academic-industry scientific partnership charged with advancing research on the role of the gut and...

Fractyl initiates Global Registry Study of the Revita System

Fractyl Health has initiated its Revita Global Registry Program, in which registry subjects will initially enrol in multiple hospitals in...

Fractyl’s Revita DMR System commercially available in Germany

Fractyl Health has announced the commercial availability of its Revita DMR System in Germany, an endoscopic procedural therapy that is...

Fractyl initiates Erase T2DM task force to establish root cause mechanisms underlying T2DM

Fractyl Health has created the Erase T2D task force, an academic-industry scientific partnership charged with advancing research on the...

Fractyl Health reports latest Revita DMR outcomes for T2DM

New data from Fractyl Health’s Revita-1 and Revita-2 studies presented at Digestive Disease Week 2022 builds on this earlier evidence to...

Two-year Revita DMR outcomes show durability of procedure in diabetics

Two-year durability data from the REVITA-1 clinical study, conducted at centres in Europe and South America, revealed that HbA1c was...

Fractyl’s pioneering Metabolic Balance Model identifies new model of intestine’s role in metabolism

Fractyl Health has announced the publication of an innovative new model of metabolism, the Metabolic Balance Model. The study synthesises...

Fractyl gains US$100 million financing to expand clinical development programs for T2DM

Fractyl Health (formerly Fractyl Laboratories) has closed a US$100 million Series F financing to support multiple late-stage clinical...

Preoperative antihypertensive drugs and visceral fat area can predict hypertension remission and recurrence post-LSG

Dec 19

Muscle-preserving weight loss drug ASC47 plus semaglutide is superior to semaglutide monotherapy for weight loss

Dec 19

Racial and ethnic groups face barriers to obtaining OMMs

Dec 19

Browse by category

Browse by tag

Weekly Digest

Get a round-up of the main headlines from Bariatric News, directly to your inbox each week.

Get in touch!
Email: info@bariatricnews.net